A man visited a hospital because of bladder discomfort, and his doctors discovered a remarkably large bladder stone.

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

There’s a new twist in the fight against bladder cancer — and it’s delivering game-changing results. In a recent clinical trial, a pretzel-shaped device that slowly releases chemotherapy drugs ...

What Is Transurethral Resection of Bladder Tumor (TURBT)? If you have bladder cancer or suspected bladder cancer, your doctor has probably told you that you need a transurethral resection of the ...

TAR-200 achieved an 82% tumor elimination rate in high-risk non-muscle-invasive bladder cancer patients resistant to previous treatments. The device releases gemcitabine into the bladder over three ...

Historic surgery, the result of years of research at Keck Medicine of USC and UCLA Health, opens the door for improved treatment of non-functioning bladders “This surgery is a historic moment in ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...